Sartorius Stedim Biotech SA
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- René Fáber
- Full Time Employees
- 10,265
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- Zone Industrielle Les Paluds Aubagne PAC France 13781
- IPO Date
- Oct 20, 1994
- Website
- sartorius.com
- Similar Companies
- Business
- Sartorius Stedim Biotech S.A. is a leading global provider of biopharmaceutical and laboratory equipment, specializing in products and services for the development, production, and quality control of biopharmaceuticals. The company’s core offerings include single-use bioreactors; filtration systems; chromatography equipment; fermentation systems; cell culture media and reagents; laboratory balances; and bioanalytical instruments. Sartorius Stedim Biotech serves customers primarily in the biopharmaceutical industry, supporting upstream and downstream processing as well as laboratory applications. Founded in 1870 and headquartered in Aubagne, France, Sartorius Stedim Biotech operates worldwide, providing solutions across Europe, the Americas, and Asia. The company is recognized for its integrated and scalable technologies designed to improve process efficiency and product quality in biopharmaceutical manufacturing. The business comprises multiple segments including bioprocess solutions and lab products and services, targeting biopharmaceutical manufacturers, research institutions, and quality control laboratories. In the last 1-2 years, Sartorius Stedim Biotech has undertaken several strategic initiatives including expanding its product portfolio through acquisitions and partnerships to enhance its single-use technologies. It has launched new bioprocessing products focused on intensified manufacturing processes and increased automation to meet growing industry demands. The company continues to execute global business expansions with an emphasis on integrating digital solutions into bioprocess workflows, furthering its strategic commitment to innovation and sustainability. Sartorius Stedim Biotech operates as a subsidiary within the broader Sartorius Group, which consolidates the company’s efforts in advancing life science research and biopharmaceutical production. This structure supports its focus on delivering high-quality, cutting-edge technologies and services to the rapidly evolving global biopharma market. The company remains committed to strengthening its market position through continuous technological advancements and operational excellence.
Company News
Baron International Growth Fund Q2 2026 Portfolio Activity
Sartorius Stedim Biotech S.A. (SRTOY) Q2 2026 Earnings Call Transcript
Sartorius Stedim Biotech S.A. (SRTOY) Q4 2025 Earnings Call Transcript
Sartorius Stedim Biotech and Nanotein Technologies Partner to Advance Cell Therapy Manufacturing
Bio Usawa Biotechnology and Sartorius Stedim Biotech Forge Partnership to Pioneer Biopharmaceutical Manufacturing in Africa
Sartorius Stedim Biotech and Sensible Biotechnologies Partner to Scale Up Sensible's Unique Cell-Based mRNA Design and Manufacturing Platform
Sartorius, Sartorius Stedim Biotech shares jump after results beat
Sartorius Stedim Biotech S.A. (SDMHF) Q3 2024 Earnings Call Transcript
Sartorius Stedim Biotech S.A. (SDMHF) H1 2024 Earnings Call Transcript
Sartorius Stedim Biotech S.A. (SDMHF) Q4 2023 Earnings Call Transcript
10 stocks for investors looking for ‘wonderful companies at a fair price'
Sartorius Stedim Biotech S.A. (SDMHF) Q3 2023 Earnings Call Transcript
Sartorius Stedim Biotech S.A. (SDMHF) Q2 2023 Earnings Call Transcript
Sartorius, Sartorius Stedim shares fall after Polyplus acquisition
Sartorius Stedim Biotech S.A. (SDMHF) Q4 2022 Earnings Call Transcript